NEW HAVEN, Conn., Dec. 24, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing therapies to treat a broad range of rare and common diseases,...Read more
In the CIRRUS-HCM trial, including interim safety results from Part D, EDG-7500 was generally well tolerated; no clinically meaningful reductions in LVEF or LVEF <50% On track to deliver full 12-week Part D readout in 2Q 2026 and Phase 3 start in 4Q...Read more
SAN DIEGO / Dec 23, 2025 / Business Wire / Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies based on its proprietary Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator...Read more
Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years...Read more
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United...Read more
AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Assertio | 9.28 1,406.29 | $9.94 |
| Nutex Health | 8.58 5.10 | $176.68 |
| Elevance Health | 6.58 1.92 | $349.88 |
| Movano Health | 5.03 161.74 | $8.14 |
| Bolt Biotherapeutics | 4.77 851.79 | $5.33 |
| Galecto | 4.65 15.77 | $34.14 |
| UnitedHealth | 4.07 1.24 | $331.65 |
| HCA Healthcare | 3.07 0.65 | $477.13 |
| Mettler-Toledo | 2.94 0.21 | $1,420.10 |
| Tenet Healthcare | 2.83 1.43 | $200.60 |
| Greenwich LifeSciences | 2.75 15.98 | $19.96 |
| Bio-Rad Laboratories | 2.13 0.71 | $303.88 |
| Apollomics | 2.01 11.17 | $20.00 |
| Prenetics Global | 1.88 12.53 | $16.88 |
| McKesson | 1.83 0.22 | $828.26 |
| Spruce Biosciences | 1.74 2.07 | $85.74 |
| Cigna | 1.65 0.60 | $276.51 |
| Thermo Fisher Scientific | 1.62 0.28 | $580.74 |
| Company | Volume | Last Trade |
|---|---|---|
| Can-Fite BioPharma | 172,526,473 | $0.22 |
| WORK Medical Technology | 50,164,958 | $0.03 |
| Aptevo Therapeutics | 38,032,985 | $0.61 |
| Reviva Pharmaceuticals | 23,413,184 | $0.31 |
| Cue Biopharma | 21,785,648 | $0.33 |
| Applied Therapeutics | 21,247,499 | $0.11 |
| Recursion | 21,203,656 | $4.25 |
| ImmunityBio | 18,815,535 | $2.14 |
| Pfizer | 18,145,255 | $25.09 |
| Incannex Healthcare | 16,024,533 | $0.40 |
| Iovance Biotherapeutics | 14,785,009 | $2.85 |
| Rezolute | 13,371,438 | $2.67 |
| Novo Nordisk | 12,870,013 | $52.40 |
| PacBio | 12,424,835 | $1.77 |
| Adicet Bio | 11,963,212 | $0.52 |
| Esperion | 11,673,340 | $4.04 |
| SELLAS Life Sciences | 10,799,171 | $2.88 |
| Sangamo Therapeutics | 10,113,778 | $0.43 |
| Tenaya Therapeutics | 10,025,729 | $0.76 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...
CLICK TO LEARN MORE
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...
CLICK TO LEARN MORE
